Skip to main content

Advertisement

Figure 5 | Molecular Cancer

Figure 5

From: Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma

Figure 5

Optimization of Tregs, CD8+and CD4+T cells in the lymph nodes, spleen and liver. Representative staining of Foxp3+ Tregs, CD8+ T cells and CD4+ T cells was shown by IHC in the lymph nodes (A), spleen (B) and liver (C) on day 5 post treatment (dark brown). Quantitative analysis of Foxp3+ Tregs, CD8+ T cells and CD4+ T cells was performed by FACs in the lymph nodes (D), spleen (E) and liver (F) on day 1 to 9 post-treatment. Control: control group; SLC: SLC group; SLC + anti-CD25: combination therapy group. Values were presented as mean ± SD; n = 5 mice/group. * P < 0.05, ** P < 0.01 vs control or indicated comparison on day 1 to 9. Results were obtained in three independent experiments. Bar = 50 μm.

Back to article page